Claims for Patent: 12,122,789

Summary for Patent: 12,122,789

Title:	Forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
Abstract:	The present invention relates to a process for the preparation of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one useful as pharmaceutically active compounds.
Inventor(s):	Roland Meier, Urs Schwitter, Anne DE PAEPE, Juergen Thun, Frank Stowasser
Assignee:	Hoffmann La Roche Inc
Application Number:	US17/233,368
Patent Claims:	1. A solid form of a compound of formula (I) wherein the solid form is crystalline Form A having an x-ray powder diffraction (XRPD) pattern comprising at least two XRPD peaks selected from the group consisting of 8.3 (±0.2) degrees two-theta, 11.4 (±0.2) degrees two-theta, 15.1 (±0.2) degrees two-theta, 15.9 (±0.2) degrees two-theta, 17.0 (±0.2) degrees two-theta. 24.0 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 2. The solid form of claim 1, wherein said solid form is crystalline Form A having an XRPD pattern comprising at least three XRPD peaks selected from the group consisting of 8.3 (±0.2) degrees two-theta, 11.4 (±0.2) degrees two-theta, 15.1 (±0.2) degrees two-theta, 15.9 (±0.2) degrees two-theta, 17.0 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 3. The solid form of claim 1, wherein the x-ray powder diffraction pattern is obtained from a Cu Kα source. 4. The solid form of claim 1, wherein said solid form is crystalline Form A having an XRPD pattern comprising XRPD peaks at 8.3 (±0.2) degrees two-theta, 11.4 (±0.2) degrees two-theta, 12.7 (±0.2) degrees two-theta, 13.0 (±0.2) degrees two-theta, 15.1 (±0.2) degrees two-theta, 15.9 (±0.2) degrees two-theta, 17.0 (±0.2) degrees two-theta, 19.7 (±0.2) degrees two-theta, 22.4 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 5. The solid form of claim 1, wherein said solid form is crystalline Form A having an XRPD pattern comprising XRPD peaks at 8.3 (±0.2) degrees two-theta, 11.4 (±0.2) degrees two-theta, 12.7 (±0.2) degrees two-theta, 13.0 (±0.2) degrees two-theta, 15.1 (±0.2) degrees two-theta, 15.4 (±0.2) degrees two-theta, 15.9 (±0.2) degrees two-theta, 16.7 (±0.2) degrees two-theta, 17.0 (±0.2) degrees two-theta, 17.5 (±0.2) degrees two-theta, 18.7 (±0.2) degrees two-theta, 19.4 (±0.2) degrees two-theta, 19.7 (±0.2) degrees two-theta, 19.8 (±0.2) degrees two-theta, 21.3 (±0.2) degrees two-theta, 22.4 (±0.2) degrees two-theta, 23.6 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, 24.7 (±0.2) degrees two-theta, 25.6 (±0.2) degrees two-theta, 26.7 (±0.2) degrees two-theta, 26.8 (±0.2) degrees two-theta, 27.4 (±0.2) degrees two-theta, 29.3 (±0.2) degrees two-theta, and 30.7 (±0.2) degrees two-theta angle of diffraction. 6. The solid form of claim 1, wherein said solid form is crystalline Form A having an IR spectrum comprising at least one peak at a position selected from the group consisting of 848 (±2) cm−1, 885 (±2) cm−1, 939 (±2) cm−1, and 1218 (±2) cm−1. 7. The solid form of claim 1, wherein said solid form is crystalline Form A having a Raman spectrum comprising at least one peak at a position selected from the group consisting of 213 (±2) cm1, 257 (±2) cm−1, 1061 (±2) cm−1, and 1570 (±2) cm−1. 8. The solid form of claim 1, wherein said solid form is crystalline Form A having a melting point above 298° C. using DSC with a heating rate of 10 K/min. 9. A pharmaceutical composition comprising the solid form of claim 1, and a pharmaceutically acceptable excipient. 10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is in a powder form. 11. A kit comprising the pharmaceutical composition of claim 9, and water as solvent for constitution of said pharmaceutical composition into an oral aqueous solution. 12. The solid form of claim 1, wherein the solid form is crystalline Form A having an XRPD pattern comprising: an XRPD peak at 8.3 degrees two-theta (±0.2) angle of diffraction; and at least two XRPD peaks selected from the group consisting of 11.4 (±0.2) degrees two-theta, 15.1 (±0.2) degrees two-theta, 15.9 (±0.2) degrees two-theta, 17.0 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 13. The solid form of claim 1, wherein the solid form is crystalline Form A having an XRPD pattern comprising: an XRPD peak at 8.3 degrees two-theta (±0.2) angle of diffraction; and at least three XRPD peaks selected from the group consisting of 11.4 (±0.2) degrees two-theta, 15.1 (±0.2) degrees two-theta, 15.9 (±0.2) degrees two-theta, 17.0 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 14. The solid form of claim 1, wherein the solid form is crystalline Form A having an XRPD pattern comprising: an XRPD peak at 8.3 degrees two-theta (±0.2) angle of diffraction; and at least four XRPD peaks selected from the group consisting of 11.4 (±0.2) degrees two-theta, 15.1 (±0.2) degrees two-theta, 15.9 (±0.2) degrees two-theta, 17.0 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 15. The solid form of claim 1, wherein the solid form is crystalline Form A having an XRPD pattern comprising: an XRPD peak at 8.3 degrees two-theta (±0.2); and at least five XRPD peaks selected from the group consisting of 11.4 (±0.2) degrees two-theta, 15.1 (±0.2) degrees two-theta, 15.9 (±0.2) degrees two-theta, 17.0 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 16. The solid form of claim 1, wherein said solid form is crystalline Form A having an XRPD pattern comprising XRPD peaks at 12.7 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 17. The solid form of claim 1, wherein said solid form is crystalline Form A having an XRPD pattern comprising XRPD peaks at 11.4 (±0.2) degrees two-theta, 12.7 (±0.2) degrees two-theta, 15.9 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 18. The solid form of claim 1, wherein said solid form is crystalline Form A having an XRPD pattern comprising XRPD peaks at 11.4 (±0.2) degrees two-theta, 15.1 (±0.2) degrees two-theta, and 25.6 (±0.2) degrees two-theta angle of diffraction. 19. The solid form of claim 1, wherein said solid form is crystalline Form A having an XRPD pattern comprising XRPD peaks at 15.1 (±0.2) degrees two-theta, 17.0 (±0.2) degrees two-theta, 25.6 (±0.2) degrees two-theta angle of diffraction. 20. The solid form of claim 1, wherein said solid form is crystalline Form A having an XRPD pattern comprising XRPD peaks at 15.1 (±0.2) degrees two-theta, 24.0 (±0.2) degrees two-theta, 25.6 (±0.2) degrees two-theta angle of diffraction. 21. The solid form of claim 1, wherein said solid form is crystalline Form A having an XRPD pattern comprising XRPD peaks at 8.3 (±0.2) degrees two-theta and 11.4 (±0.2) degrees two-theta; 8.3 (±0.2) degrees two-theta and 15.1 (±0.2) degrees two-theta, 8.3 (±0.2) degrees two-theta and 15.9 (±0.2) degrees two-theta; or 8.3 (±0.2) degrees two-theta and 17.0 (±0.2) degrees two-theta angle of diffraction. 22. The solid form of claim 14, wherein the x-ray powder diffraction pattern is obtained from a Cu Ka source. 23. The solid form of claim 21, wherein the x-ray powder diffraction pattern is obtained from a Cu Ka source. 24. A pharmaceutical composition comprising the solid form of claim 2, and a pharmaceutically acceptable excipient. 25. A pharmaceutical composition comprising the solid form of claim 12, and a pharmaceutically acceptable excipient. 26. A pharmaceutical composition comprising the solid form of claim 13, and a pharmaceutically acceptable excipient. 27. A pharmaceutical composition comprising the solid form of claim 14, and a pharmaceutically acceptable excipient. 28. A pharmaceutical composition comprising the solid form of claim 15, and a pharmaceutically acceptable excipient. 29. A pharmaceutical composition comprising the solid form of claim 21, and a pharmaceutically acceptable excipient. 30. The solid form of claim 1, wherein said solid form is crystalline Form A, having an IR spectrum comprising at least three peaks at positions selected from the group consisting of 848 (±2) cm−1, 885 (±2) cm−1, 939 (±2) cm1, and 1218 (±2) cm−1. 31. The solid form of claim 1, wherein said solid form is crystalline Form A having a Raman spectrum comprising at least three peaks at positions selected from the group consisting of 213 (±2) cm−1, 257 (±2) cm−1, 1061 (±2) cm−1, and 1570 (±2) cm−1.